Horizon's Revised TED Indication Should Help Tepezza

Just four days after unveiling top-line data from a Phase IV study on the efficacy of thyroid eye disease (TED) drug Tepezza, Horizon Therapeutics plc got an updated indication from the US Food and Drug Administration for the biologic, which analysts said might encourage payers to cover the drug in patients with less-severe disease. Tepezza (teprotumumab) is a key driver of Amgen, Inc.’s $27.8bn buyout of Horizon, and analysts said broader use is necessary to assure the deal is viable financially.

The updated indication specifies that Tepezza is appropriate for treatment of both acute and chronic TED, a progressive, vision-threatening rare autoimmune disease. The initial indication covered TED broadly; Horizon ran...